You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

RAYOS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Rayos patents expire, and what generic alternatives are available?

Rayos is a drug marketed by Horizon and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in twenty-nine countries.

The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the prednisone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rayos

A generic version of RAYOS was approved as prednisone by WATSON LABS on December 31st, 1969.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RAYOS?
  • What are the global sales for RAYOS?
  • What is Average Wholesale Price for RAYOS?
Summary for RAYOS
International Patents:53
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 89
Patent Applications: 2,802
Drug Prices: Drug price information for RAYOS
What excipients (inactive ingredients) are in RAYOS?RAYOS excipients list
DailyMed Link:RAYOS at DailyMed
Drug patent expirations by year for RAYOS
Drug Prices for RAYOS

See drug prices for RAYOS

Pharmacology for RAYOS
Paragraph IV (Patent) Challenges for RAYOS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAYOS Delayed-release Tablets prednisone 5 mg 202020 1 2012-11-26

US Patents and Regulatory Information for RAYOS

RAYOS is protected by seven US patents.

Patents protecting RAYOS

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,GASTROINTESTINAL,DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed release tablet with defined core geometry
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Delayed-release glucocorticoid treatment of rheumatoid disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RAYOS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RAYOS

See the table below for patents covering RAYOS around the world.

Country Patent Number Title Estimated Expiration
South Africa 200809858 Delayed-release glucocorticoid treatment of rheumatoid disease ⤷  Sign Up
Japan 2002539167 ⤷  Sign Up
Tunisia SN08385 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE ⤷  Sign Up
European Patent Office 2049123 TRAITEMENT GLUCOCORTICOÏDIQUE À LIBÉRATION RETARDÉE DE MALADIE RHUMATOÏDE (DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE) ⤷  Sign Up
Denmark 1631251 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.